# US 2001/0025028 A1 · Methods of inhibiting bone resorption

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025028 A1
- Document ID: US20010025028A1
- Status: Published application
- Kind: A1
- Application number: 09/833,185
- Filed: 2001-04-11
- Published: 2001-09-27
- Earliest claimed: 1998-03-13
- Assignees: Merck & Co., Inc.
- Inventors: John E. Fisher; Gideon A. Rodan
- Web page: https://patentgrep.com/patent/US20010025028A1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods of inhibiting bone resorption comprising administering a therapeutically effective amount of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

## Claims

### Claim 1

A method of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of a HMG-CoA reductase inhibitor to a mammal in need thereof.

### Claim 2 (depends on 1)

A method according to claim 1 wherein said mammal is a human.

### Claim 3 (depends on 2)

A method according to claim 2 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, mevastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

### Claim 4 (depends on 3)

A method according to claim 3 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

### Claim 5 (depends on 4)

A method according to claim 4 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvaststin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

### Claim 6

A method of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones to a mammal in need thereof.

### Claim 7 (depends on 6)

A method according to claim 6 wherein said mammal is a human.

### Claim 8 (depends on 7)

A method according to claim 7 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, mevastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

### Claim 9 (depends on 8)

A method according to claim 8 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

### Claim 10 (depends on 9)

A method according to claim 9 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvaststin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

### Claim 11 (depends on 7)

A method according to claim 7 wherein said organic bisphosphonate is selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zolendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.

### Claim 12 (depends on 11)

A method according to claim 11 wherein said organic bisphosphonate is alendronate and the pharmaceutically acceptable salts thereof.

### Claim 13 (depends on 12)

A method according to claim 12 wherein said organic bisphosphonate is alendronate monosodium trihydrate.

### Claim 14 (depends on 7)

A method according to claim 7 wherein said estrogen receptor modulator is selected from the group consisting of estrogen, progestins, estradiol, raloxifene, and tamoxifene, and their pharmaceutically acceptable salts, and mixtures thereof.

### Claim 15 (depends on 7)

A method according to claim 7 wherein said peptide hormone is selected from the group consisting of human calcitonin, salmon calcitonin, and mixtures thereof.

### Claim 16

A pharmaceutical composition comprising a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormone.

### Claim 17 (depends on 16)

A composition according to claim 16 which further comprises a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

A composition according to claim 17 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, mevastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

### Claim 19 (depends on 17)

A composition according to claim 17 wherein said organic bisphosphonate is selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zolendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.

### Claim 20 (depends on 17)

A composition according to claim 17 wherein said estrogen receptor modulator is selected from the group consisting of estrogen, progestins, estradiol, raloxifene, and tamoxifene, and their pharmaceutically acceptable salts, and mixtures thereof.

### Claim 21 (depends on 17)

A composition according to claim 17 wherein said peptide hormone is selected from the group consisting of human calcitonin, salmon calcitonin, and mixtures thereof.

### Claim 22

A method of treating or preventing a disease state involving abnormal bone resorption comprising administering a therapeutically effective amount of a HMG-CoA reductase inhibitor to a mammal in need thereof.

### Claim 23 (depends on 22)

A method according to claim 22 wherein said disease state is osteoporosis.

### Claim 24

A method of treating or preventing a disease state involving abnormal bone resorption comprising administering a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones to a mammal in need thereof.

### Claim 25 (depends on 24)

A method according to claim 24 wherein said disease state is osteoporosis.
